Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01720264

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).

Status: 
Recruiting
Study Date: 
Mon, 06/06/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Sitagliptin Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3. Other Name: Januvia